X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5) 5
index medicus (5) 5
drug delivery systems (4) 4
intestine-specific delivery (4) 4
animals (3) 3
bioavailability (3) 3
cholesterol (3) 3
intestine-specific inhibitor (3) 3
apolipoprotein b (2) 2
bioaccessibility (2) 2
bioactive compounds (2) 2
biological products (2) 2
cardiovascular diseases - etiology (2) 2
cardiovascular diseases - prevention & control (2) 2
carrier proteins - metabolism (2) 2
cholesterol, ldl - blood (2) 2
controlled-release (2) 2
drug-delivery (2) 2
encapsulation (2) 2
familial hypercholesterolemia (2) 2
food science & technology (2) 2
gene expression (2) 2
hyperlipidemia (2) 2
hyperlipoproteinemia type ii - drug therapy (2) 2
intestine (2) 2
intestine-specific (2) 2
pharmacology & pharmacy (2) 2
statin-intolerant patients (2) 2
thyroid-hormone receptor (2) 2
triglyceride transfer protein (2) 2
[sdv.bbm.bc]life sciences [q-bio]/biochemistry, molecular biology/biomolecules [q-bio.bm] (1) 1
[spi.gproc]engineering sciences [physics]/chemical and process engineering (1) 1
absorption (1) 1
adsorption (1) 1
anemia (1) 1
angiotensin-converting-enzyme (1) 1
animals, genetically modified (1) 1
anti-il-12 antibodies (1) 1
anti-sense oligonucleotides (1) 1
anticancer properties (1) 1
anticholesteremic agents (1) 1
anticholesteremic agents - adverse effects (1) 1
anticholesteremic agents - pharmacokinetics (1) 1
anticholesteremic agents - therapeutic use (1) 1
antisense oligonucleotide (1) 1
apolipoprotein a-iv (1) 1
apolipoproteinb inhibitors (1) 1
apolipoproteins b - blood (1) 1
apolipoproteins b - genetics (1) 1
article (1) 1
autosomal-dominant hypercholesterolemia (1) 1
b synthesis inhibition (1) 1
b-containing lipoproteins (1) 1
background: advances in mucosal immunology have revealed a broad set of new therapeutic targets to resolve inflammation and symptoms in patientswith inflammatory bowel diseases. objective: despite the enormous success of anti-tnf therapies in ibd, these treatments have limited efficacy, and there continues to be concerns regarding their toxicity. thus, a considerable unmet need exists for better treatment of these disorders. methods: new therapeutic targets include other pro-inflammatory cytokines such as il-6, il-12, il-17 or ifn- (1) 1
bamboo (1) 1
barriers (1) 1
belgrade (1) 1
beta-carotene (1) 1
beta-lactoglobulin (1) 1
binding (1) 1
binding sites (1) 1
biochemistry & molecular biology (1) 1
biochemistry, molecular biology (1) 1
biology (1) 1
biomarkers - blood (1) 1
biomimetic materials - therapeutic use (1) 1
biomolecules (1) 1
biotechnology & applied microbiology (1) 1
blotting, western (1) 1
cancer (1) 1
captopril (1) 1
captopril montmorillonite (1) 1
cardiac patients (1) 1
cardiovascular diseases - blood (1) 1
cardiovascular diseases - genetics (1) 1
carrier proteins - antagonists & inhibitors (1) 1
catalyzed oxidation (1) 1
cdx2 protein (1) 1
cellulose (1) 1
charcoal (1) 1
chemical and process engineering (1) 1
chemical properties (1) 1
chemistry (1) 1
chemistry, applied (1) 1
chemistry, multidisciplinary (1) 1
chemistry, organic (1) 1
chemistry/food science, general (1) 1
chickens (1) 1
chitosan (1) 1
cholesterol ester transfer protein inhibitors (1) 1
chylomicrons (1) 1
clay (1) 1
colon (1) 1
colon cancer (1) 1
complex coacervation (1) 1
composites spherical microparticles (1) 1
condensed matter physics (1) 1
conserved sequence (1) 1
controlled release (1) 1
coronary heart disease (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pharmaceuticals (Basel, Switzerland), ISSN 1424-8247, 07/2019, Volume 12, Issue 3, p. 109
Hydrophobic drug nanocrystals (NCs) manufactured by particle engineering have been extensively investigated for enhanced oral bioavailability and therapeutic... 
fenofibrate | media milling | bioavailability | nanocrystals | intestine-specific delivery | composites spherical microparticles
Journal Article
Lin ye ke xue = Scientia Silvae Sinicae, ISSN 1001-7488, 01/2018, Issue 6, p. 125
Journal Article
Research Journal of Pharmaceutical, Biological and Chemical Sciences, 10/2011, Volume 2, Issue 4, pp. 662 - 675
Journal Article
Molecular Therapy, ISSN 1525-0016, 03/2019, Volume 27, Issue 3, pp. 493 - 506
Nanoparticles (NPs) have been utilized to deliver drugs to the intestinal epithelium . Moreover, NPs derived from edible plants are less toxic than synthetic... 
Slc11a2 | hepcidin | serum ferritin | Ussing chamber | NTBI | Dmt1 intestine-specific knockout mice | hepcidin knockout mice | MEDICINE, RESEARCH & EXPERIMENTAL | DIETARY IRON | TRANSPORTER | MOUSE | SLC11A2 | GENE | BELGRADE | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | MUTATION | GENETICS & HEREDITY | MICROCYTIC ANEMIA | ABSORPTION | EXPRESSION
Journal Article
International Journal of Molecular Sciences, ISSN 1661-6596, 01/2017, Volume 18, Issue 1, pp. 196 - 196
Journal Article
Pharmacology and Therapeutics, ISSN 0163-7258, 07/2012, Volume 135, Issue 1, pp. 31 - 43
Elevated low density lipoprotein cholesterol (LDL-C) levels have been associated with an increased risk for cardiovascular disease (CVD). Despite a 25–30%... 
Apolipoprotein B | PCSK9 inhibitor | MTP inhibitor | Thyromimetics | Anti-sense oligonucleotides | TRIGLYCERIDE TRANSFER PROTEIN | NONHUMAN-PRIMATES | FAMILIAL HYPERCHOLESTEROLEMIA | ANTISENSE OLIGONUCLEOTIDE | LDL CHOLESTEROL | INTESTINE-SPECIFIC INHIBITOR | PLASMA-CHOLESTEROL | PHARMACOLOGY & PHARMACY | THYROID-HORMONE RECEPTOR | HUMAN APOLIPOPROTEIN B-100 | Proprotein Convertases - antagonists & inhibitors | Cardiovascular Diseases - prevention & control | Humans | Apolipoproteins B - blood | Cardiovascular Diseases - genetics | Hypercholesterolemia - drug therapy | Oligonucleotides, Antisense - therapeutic use | Cardiovascular Diseases - blood | Cholesterol, LDL - blood | Biomimetic Materials - therapeutic use | Cardiovascular Diseases - etiology | Hypercholesterolemia - blood | Down-Regulation | Proprotein Convertases - metabolism | Carrier Proteins - antagonists & inhibitors | Treatment Outcome | Apolipoproteins B - genetics | Biomarkers - blood | Anticholesteremic Agents - adverse effects | Anticholesteremic Agents - pharmacokinetics | Animals | Anticholesteremic Agents - therapeutic use | Carrier Proteins - metabolism | Protein Kinase Inhibitors - therapeutic use | Thyroid Hormones - metabolism | Hypercholesterolemia - complications | Serine Endopeptidases - metabolism | Hypercholesterolemia - genetics | Proprotein Convertase 9 | Hypercholesterolemia | RNA | Low density lipoproteins | Cytochrome P-450 | Triglycerides | Coronary heart disease | Health aspects | Cholesterol | Lipoprotein A
Journal Article